

Please type a plus sign (+) inside this box ? ☐

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (use as many sheets as necessary)			
		Application Number	09/507,968
		Filing Date	February 22, 2000
		First Named Inventor	YU et al.,
		Group Art Unit	1646 1647
		Examiner Name	Maria P. B. Bummer
Sheet	1	of	4
		Attorney Docket Number	PF343P3

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	U.S. Patent Document Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
SCP	A1	08/984,396		SmithKline Beecham	NA	Priority Document of EP 869180
	A2	60/033,601		Schering	NA	Priority Document of WO 98/27114
	A3	60/041,797		SmithKline Beecham	NA	Priority Document of EP 869180
	A4	60/048,776		Regeneron	NA	Priority Document of 98/55620 & 98/55621
	A5	60/058,786		Biogen	NA	Priority Document of 99/12964
	A6	60/066,386		Regeneron	NA	Priority Document of 98/55620 & 98/55621
	A7	60/066,577		Eli Lilly	NA	Priority Document of EP 921194
	A8	60/068,959		Chiron	NA	Priority Document of WO 99/33980
	A9	60/096,173		Eli Lilly	NA	Priority Document of EP 921194
	A10	60/106,976		U.S. Government - DHHS	NA	Priority Document of WO 00/26244
	A11	60/117,169		Biogen	NA	Priority Document of WO 00/43032
	A12	60/143,228		Biogen	NA	Priority Document of WO 00/43032

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No. ¹	Foreign Patent Document		Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
Office ³	Number ⁴							
S&D	A13	EP	869180	A1	SmithKline Beecham	07-10-1998	—	—
	A14	EP	921194	A2	Eli Lilly	06-09-1999	—	—
	A15	EP	98302526	—	SmithKline Beecham	—	Priority Document of EP 869180	—
	A16	EP	98309632	—	Eli Lilly	—	Priority Document of EP 921194	—
	A17	WO	01/40466	A2	Genentech	06-07-2001	Pages 1-135 and Figures 23 and 24	—
	A18	WO	00/26244	A2	U.S. Government - DHHS	05-11-2000	—	—
	A19	WO	00/39295	A1	Glaxo	07-06-2000	—	—
	A20	WO	00/40716	A2	Zymogenetics	07-13-2000	—	—
	A21	WO	00/43032	A2	Biogen	07-27-2000	—	—
	A22	WO	00/47740	A2	Amgen, Inc.	08-17-2000	—	—
	A23	WO	00/45836	A1	Res. Dev. Foundation	08-10-2000	—	—
	A24	WO	00/60079	A2	Chiron Corporation	10-12-2000	—	—
A25	WO	00/67034	A1	Immunex Corporation	11-09-2000	—	—	

Sarada Prasad

10/31/01

Bridget C. Bummer 8/24/03

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

Please type a plus sign (+) inside this box ?



PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT ON PATENT APPLICATION (use as many sheets as necessary)		Application Number	09/507,968
		Filing Date	February 22, 2000
		First Named Inventor	YU et al.,
		Group Art Unit	1646 1647
		Examiner Name	Mortiz, P. B. Bunner
Sheet 2	of 4	Attorney Docket Number	PF343P3

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
SEP	A26	WO	00/68378	A1	National Jewish Medical and Research Center	11-16-2000		
	A27	WO	00/77256	A1	Human Genome Sciences	12-21-2000		
	A28	WO	97/33902	A1	Human Genome Sciences	09-18-1997		
	A29	WO	98/27114	A2	Schering	06-25-1998		
	A30	WO	98/55620	A1	Regeneron	12-10-1998		
	A31	WO	98/55621	A1	Regeneron	12-10-1998		
	A32	WO	99/11791	A1	Univ. of Washington	03-11-1999		
	A33	WO	99/12964	A2	Biogen	03-18-1999		
	A34	WO	99/33980	A2	Chiron	07-08-1999		

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶	
SEP 				

Bridget E. Bunner 8/26/03

Sarada Prasad 10/31/01

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

Please type a plus sign (+) inside this box ?



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete If Known		
INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (use as many sheets as necessary)		Application Number	09/507,968	
		Filing Date	February 22, 2000	
		First Named Inventor	YU et al.,	
		Group Art Unit	1646 1647	
		Examiner Name	Mertz, P. B. Bunner	
Sheet	of	4	Attorney Docket Number	PF343P3

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
BOB	82P	A48 BAUMGARTH, Nicole, Secreted IgM versus BlyS in germinal center formation, Nature Immunology, (2000) 1:179.	
		A49 CYSTER, JASON G., Marginal zone B cells may steal the limelight as the roles of Pyk-2 and BlyS begin to be elucidated. Pyk-2 deficiency leads to their loss whereas signaling via the BlyS receptor may augment their function, Nature Immunology, (2000) 1:9-10.	
		A50 DO ET AL., Attenuation of Apoptosis Underlies B Lymphocyte Stimulator Enhancement of Humoral Immune Response, J. Exp. Med., (2000) 192:953-964.	
		A51 GROSS ET AL., TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease, Nature, (2000) 404:995-999.	
		A52 HATZOGLOU ET AL., TNF Receptor Family Member BCMA (B Cell Maturation) Associates with TNF Receptor-Associated Factor (TRAF) 1, TRAF2, TRAF3 and Activates NF-κB, Elk-1, c-Jun N-Terminal Kinase, and p38 Mitogen-Activated Protein Kinase, The Journal of Immunology, (2000) 165:1322-1330.	
		A53 HU ET AL., Characterization of TNFRSF19, a novel member of the tumor necrosis factor receptor superfamily, Genomics, 62:1023-107 (1999).	
		A54 KANAKARAJ ET AL., BlyS Binds to B Cells With High Affinity and Induces Activation of the Transcription Factors NF-κ and Elf-1, Cytokine (2001) 13:25-31.	
		A55 KHARE ET AL., Severe B Cell Hyperplasia and autoimmune disease in TALL-1 transgenic mice, PNAS, (2000) 97:3370-3375.	
		A56 LAABI ET AL., Lymphocyte Survival--Ignorance is BlyS, Science Magazine, (2001) 289:883.	
		A57 MACKAY ET AL., Mice Transgenic for BAFF Develop Lymphocytic Disorders Along with Autoimmune Manifestations, J. Exp. Med., (1999) 190:1697-1710.	
		A58 MARSTERS, ET AL., Interaction of the TNF homologues BlyS and APRIL with the TNF receptor homologues BCMA and TACI, Current Biology, (2000) 10:785-788.	
		A59 MOORE ET AL., BlyS: Member of the Tumor Necrosis Factor Family and B Lymphocyte Stimulator, Science, (1999) 285:260-263.	
		A60 NARDELLI ET AL., Synthesis and release of B-lymphocyte stimulator from myeloid cells, Immunobiology, (2001) 97:198-204.	
		A61 PARRY ET AL., Pharmacokinetics and Immunological Effects of Exogenously administered Recombinant Human B Lymphocyte Stimulator (BlyS) in Mice, The Journal of Pharmacology and Experimental Therapies, (2001) 296:396-404.	
		A62 SCHNEIDER ET AL., BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth, J. Exp. Med., (1999) 189:1747-1756.	
BOB		A63 SHU ET AL., TALL-1 is a novel member of the TNF Family that is Down-regulated by Mitogens, J. Leukoc. Biol., 65:680-683 (1999).	

Bridget E. Bunner 8/26/03
Sarada Prasad 10/31/01

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

Please type a plus sign (+) inside this box ? ☐

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. Department of Commerce

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (use as many sheets as necessary)			
		Application Number	09/507,968
		Filing Date	February 22, 2000
		First Named Inventor	YU et al.,
		Group Art Unit	1646 1647
		Examiner Name	Mertz, P. B. Bunner
Sheet	4	of	4
		Attorney Docket Number	PF343P2

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
Bob	A64	THOMPSON ET AL., BAFF Binds to the Tumor Necrosis Factor Receptor-like Molecule B Cell Maturation Antigen and Is Important for Maintaining the Peripheral B Cell Population, J. Exp. Med., (2000) 192:129-135.	
	A65	WU ET AL., Tumor Necrosis Factor (TNF) Receptor Superfamily Member TACI Is a High Affinity Receptor for TNF Family Members APRIL and BlyS, The Journal of Biological Chemistry (2000) 275:34578-34585.	
	A66	XIA ET AL., TACI Is a TRAF-interacting Receptor for TALL-1, a Tumor Necrosis Factor Family Member Involved in B Cell Regulation, J. Exp. Med., (2000) 192:137-143.	
	A67	YAN ET AL., Identification of a receptor for BlyS demonstrates a crucial role in humoral immunity, Nature Immunology, (2000) 1:37-41.	
	A68	YU ET AL., APRIL and TALL-1 and receptors BCMA and TACI: system for regulating humoral immunity, (2000) 1:252-256.	
	A69	ZHANG ET AL., Cutting Edge: A Role for B Lymphocyte Stimulator in Systemic Lupus Erythematosus, The Journal of Immunology, (2001) 166:6-10.	
Bob			

Examiner	Sarada Iwasaki	Date Considered	10/31/01
----------	----------------	-----------------	----------

Bridge E. Bunner 8/26/03

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.